Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1192 in Moderate to Severe Refractory SLE
NCT07031713Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT1192 in systemic lupus erythematosus (SLE). Primary endpoints: Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest at 12 months and Maximum Tolerated Dose at 28 days. Started Jul 2025; status: recruiting.
02
Drugs
CT1192
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07031713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07031713.